New research published today in a report from the IMS Institute for Healthcare Informatics - Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, highlights the opportunity for biosimilars to create savings of approx USD 110 billion for health systems across Europe and the U.S over the next five years. The report highlights that the extent to which biosimilars will provide these forecasted savings will depend on the policy and implementation approaches adopted by country healthcare systems.
The report, funded by Novartis, will strengthen the healthcare community's understanding of the requirements for a competitive functioning biologics market. The learnings and insights from this study will help the community to achieve its full potential for the benefit of patients, healthcare professionals and payors.
To read the IMS Institute for Healthcare Informatics’ press release click here and their full report click here.
Sandoz, a Novartis company, is the pioneer and a global market leader in biosimilars.
Sandoz, a Novartis company, is a global leader in generic pharmaceuticals and biosimilars, driving sustainable access to high-quality healthcare. Sandoz supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz portfolio comprises approximately 1,100 molecules, which accounted for 2015 sales of USD 9.2 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area. The company holds leading global positions in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines.